Actavis releases trandolapril capsules
Icelandic generic drugmaker Actavis has released its generic antihypertensive drug trandolapril in capsule form, with 0.5mg,1mg, 2mg and 4mg dose versions, in the UK.
Trandolapril is the generic version of Abbott Laboratories' Mavik. Brand and generic versions of this product had total US sales of around $34.0 million for the 12 months ending Dececember 31, 2007, according to IMS Health.
Marketing director Jonathan Wilson said the drug is "another excellent addition to our portfolio of products, that has grown by more than 25 in the last year."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze